Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-030575
Filing Date
2024-08-07
Accepted
2024-08-07 17:15:11
Documents
92
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1202218
2 ex31-1.htm EX-31.1 17512
3 ex31-2.htm EX-31.2 17556
4 ex32-1.htm EX-32.1 7950
  Complete submission text file 0001493152-24-030575.txt   7650672

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE hrow-20240630.xsd EX-101.SCH 55434
6 XBRL CALCULATION FILE hrow-20240630_cal.xml EX-101.CAL 84083
7 XBRL DEFINITION FILE hrow-20240630_def.xml EX-101.DEF 308725
8 XBRL LABEL FILE hrow-20240630_lab.xml EX-101.LAB 501554
9 XBRL PRESENTATION FILE hrow-20240630_pre.xml EX-101.PRE 436694
95 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1183087
Mailing Address 102 WOODMONT BLVD SUITE 610 NASHVILLE TN 37215
Business Address 102 WOODMONT BLVD SUITE 610 NASHVILLE TN 37215 615.733.4731
HARROW, INC. (Filer) CIK: 0001360214 (see all company filings)

EIN.: 450567010 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35814 | Film No.: 241184996
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)